Exstent Appoints Matt Thompson as CEO to Lead Next Phase of Global Expansion
Exstent, a UK-based medical device company specializing in personalized external aortic support, has appointed Matt Thompson as Chief Executive Officer. The leadership change marks a strategic move as the company prepares for global expansion and broader adoption of its Exovasc technology.
Thompson brings more than 20 years of combined clinical and commercial experience to his new role. Before joining Exstent, he served as President and CEO of Endologix, where he oversaw the company’s portfolio growth and its 2021 acquisition of PQ Bypass. Earlier in his career, he was Professor of Vascular Surgery at St George’s Hospital, University of London, and Consultant Vascular Surgeon at St George’s Vascular Institute. His background in integrating innovative vascular technologies into established markets aligns with Exstent’s growth strategy.
“Exstent’s personalised external aortic support is a meaningful advance in managing ascending aortic disease,” said Matt Thompson. “It preserves the native anatomy and offers a less invasive alternative to open graft replacement. My focus is to build on the company’s strong clinical foundation, expand access through collaboration, and position Exstent for sustainable growth.”
Exstent’s flagship product, the Exovasc implant, is a custom-designed external support that reinforces the aorta to prevent dilation and dissection. More than 1,500 patients across 40 leading cardiac centers in the UK, Europe, and Australia have been treated with the device. Long-term clinical data have shown strong outcomes in safety, valve preservation, and durability. The company is now scaling manufacturing and seeking partnerships to support wider clinical use.
Peter Phillips, Chair of Exstent, said, “Exstent is entering a significant phase of expansion. Matt’s clinical expertise and commercial leadership will be instrumental as we move from strong foundations to broader adoption.” Founded in 2002 and headquartered in Tewksbury, Exstent continues to advance personalized approaches to treating aortic disease worldwide.
